文献速递慢病管理预防保健、筛查与疫苗

基层慢性肾病床旁检测优化试点研究

A pilot point-of-care kidney disease clinic in primary care to pharmacologically optimise people with chronic kidney disease (PROTECT KIDNEY).
PubMed 文献 · Fam Pract · 2025-01-01

本研究在英国大伦敦地区三家全科诊所开展质量改进试点,评估基于床旁检测(POCT)的蛋白尿性慢性肾病(CKD)药物优化路径的可行性与可接受性;48例合格患者中25例(52%)参与,20/25(80%)实现药物优化,无显著不良事件,患者满意度高,但招募与参与仍存障碍。

要点

  • POCT肌酐与钾结合交通灯式决策支持可支持实时用药决策
  • 25例参与者中20例(80%)实现药物优化,无显著不良事件
  • POCT检测成功44/57(77%),满意度12/13(92%),招募率52%

核心结论

  • 基于POCT的CKD优化路径在基层可行且接受度高,但招募与参与障碍仍存,需进一步评估可扩展性、长期临床影响与成本效益。

研究设计与样本

  • 在英国大伦敦地区三家全科诊所开展的质量改进试点研究,对象为18-80岁、伴高血压和/或2型糖尿病、有蛋白尿且eGFR 30-75 ml/min/1.73m2的成人,通过电子健康记录识别。

主要发现

  • 48例合格患者中25例(52%)同意参与,23/25(92%)完成路径,20/25(80%)实现药物优化,无显著不良事件。
  • POCT检测成功44/57(77%),多数参与者耐受良好(10/13;77%),满意度高(12/13;92%),多数人希望未来由高级执业护士或药师出诊。

关键数值与推荐

  • 纳入标准:成人18-80岁,伴高血压和/或2型糖尿病、蛋白尿、eGFR 30-75 ml/min/1.73m2。
  • 主要结局为招募率与患者可接受性;次要疗效结局包括药物优化与肾功能变化。

临床怎么用

  • 可在基层对蛋白尿性CKD患者采用POCT肌酐和钾结合交通灯式决策支持,实现实时决策与药物优化。
  • 未来诊所可由高级执业护士或药师主导,以提高患者接受度。

局限性

  • 为三家诊所的小样本试点质量改进研究,招募率仅52%,长期临床影响与成本效益尚未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic kidney disease (CKD) is increasing in prevalence and is associated with substantial morbidity and mortality. Early initiation of cardiorenal protective medications is recommended to improve outcomes. Barriers to implementation include renal function monitoring and resources to initiate and titrate treatment. We aimed to evaluate the feasibility and acceptability of a protocolled point-of-care testing (POCT) pathway to optimise people living with proteinuric CKD in primary care. METHOD: A pilot quality improvement study conducted across three general practices in Greater London, United Kingdom. Inclusion criteria were adults (18-80 years) with hypertension and/or type 2 diabetes mellitus, proteinuria, and reduced kidney function (eGFR 30-75 ml/min/1.73m2), who were identified using electronic health records. POCT for creatinine and potassium enabled real-time decision-making using a traffic light clinical decision support system. The primary outcome was recruitment rate and patient acceptability. Secondary efficacy outcomes included medication optimisation and renal function changes. RESULTS: Twenty-five (52%) of 48 patients agreed to participate. Overall, 23/25 (92%) completed the pathway and 20/25 (80%) achieved pharmacological optimisation. There were no significant adverse events. POCT was successful in 44/57 (77%) of cases and well tolerated by most participants (10/13; 77%). Patient satisfaction was high (12/13; 92%), with most preferring advanced nurse practitioners or pharmacists in future clinics. CONCLUSION: A POCT-led CKD optimisation pathway is feasible and well-accepted in primary care. While high medication optimisation rates were achieved, barriers to recruitment and engagement remain. Future studies should evaluate scalability, long-term clinical impact, and cost-effectiveness to inform wider implementation. Chronic kidney disease is becoming more common and may lead to serious health problems. This can be difficult for GP practices to manage because of limited time and staff. This study tested a new way to give people with kidney disease the right treatment using finger-prick blood tests at their local GP surgery to check their kidney function. These tests give quick results so healthcare staff can make fast decisions about care. The study happened in three practices in London. Out of 48 people we identified, 25 agreed to take part. Most people (92%) completed the process, 20 out of 25 (80%) had their kidney treatments optimised safely. The finger-prick tests had approximately a 75% success rate and were well received by people taking part. Most people said they were very satisfied with the care they received during the clinics. In summary, this new way of managing kidney disease in primary care worked well and people who took part had positive experiences. More work needs to be done to see if it can be used on a wider scale.

来源:Fam Pract,查看原文。版权归原作者所有。

引用

  1. Gama RM, Griffiths K, Beencke N, et al. A pilot point-of-care kidney disease clinic in primary care to pharmacologically optimise people with chronic kidney disease (PROTECT KIDNEY). Fam Pract. 2025. PMID: 41165433. doi:10.1093/fampra/cmaf083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。